Adage Capital Partners Gp, L.L.C. C4 Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 200,000 shares of CCCC stock, worth $542,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200,000
Previous 1,550,000
87.1%
Holding current value
$542,000
Previous $2.48 Million
88.47%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CCCC
# of Institutions
105Shares Held
57.2MCall Options Held
15.2KPut Options Held
0-
Wasatch Advisors Inc Salt Lake City, UT7.42MShares$20.1 Million0.06% of portfolio
-
Lynx1 Capital Management LP San Juan, PR7.1MShares$19.2 Million3.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$18.9 Million0.77% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$18.5 Million0.35% of portfolio
-
Morgan Stanley New York, NY4.75MShares$12.9 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $133M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...